Oxygen Exposure Resulting in Arterial Oxygen Tensions Above the Protocol Goal Was Associated With Worse Clinical Outcomes in Acute Respiratory Distress Syndrome

Objectives: High fractions of inspired oxygen may augment lung damage to exacerbate lung injury in patients with acute respiratory distress syndrome. Participants enrolled in Acute Respiratory Distress Syndrome Network trials had a goal partial pressure of oxygen in arterial blood range of 55–80 mm Hg, yet the effect of oxygen exposure above this arterial oxygen tension range on clinical outcomes is unknown. We sought to determine if oxygen exposure that resulted in a partial pressure of oxygen in arterial blood above goal (> 80 mm Hg) was associated with worse outcomes in patients with acute respiratory distress syndrome. Design: Longitudinal analysis of data collected in these trials. Setting: Ten clinical trials conducted at Acute Respiratory Distress Syndrome Network hospitals between 1996 and 2013. Subjects: Critically ill patients with acute respiratory distress syndrome. Interventions: None. Measurements and Main Results: We defined above goal oxygen exposure as the difference between the fraction of inspired oxygen and 0.5 whenever the fraction of inspired oxygen was above 0.5 and when the partial pressure of oxygen in arterial blood was above 80 mm Hg. We then summed above goal oxygen exposures in the first five days to calculate a cumulative above goal oxygen exposure. We determined the effect of a cumulative 5-day above goal oxygen exposure on mortality prior to discharge home at 90 days. Among 2,994 participants (mean age, 51.3 yr; 54% male) with a study-entry partial pressure of oxygen in arterial blood/fraction of inspired oxygen that met acute respiratory distress syndrome criteria, average cumulative above goal oxygen exposure was 0.24 fraction of inspired oxygen-days (interquartile range, 0–0.38). Participants with above goal oxygen exposure were more likely to die (adjusted interquartile range odds ratio, 1.20; 95% CI, 1.11–1.31) and have lower ventilator-free days (adjusted interquartile range mean difference of –0.83; 95% CI, –1.18 to –0.48) and lower hospital-free days (adjusted interquartile range mean difference of –1.38; 95% CI, –2.09 to –0.68). We observed a dose-response relationship between the cumulative above goal oxygen exposure and worsened clinical outcomes for participants with mild, moderate, or severe acute respiratory distress syndrome, suggesting that the observed relationship is not primarily influenced by severity of illness. Conclusions: Oxygen exposure resulting in arterial oxygen tensions above the protocol goal occurred frequently and was associated with worse clinical outcomes at all levels of acute respiratory distress syndrome severity. Dr. Aggarwal contributed to this article as an employee of Johns Hopkins University. The views expressed in this article are his own and those of Johns Hopkins University School of Medicine, and do not necessarily represent the views of the National Institutes of Health or the U.S. government. Drs. Aggarwal, Brower, and Checkley contributed in conception and design of the work. Drs. Aggarwal and Checkley contributed in analysis and interpretation of the data. Drs. Aggarwal, Brower, Hager, Thompson, Netzer, and Shanholtz, Mr. Lagakos, and Dr. Checkley contributed in drafting the article for important intellectual content. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (http://ift.tt/29S62lw). Supported, in part, by grant from National Heart, Lung, and Blood Institute (NHLBI) Contracts NO1-HR-46054 through 46064 and NO1-HR 56165 through 56179 with the National Institutes of Health, NHLBI. The funding agencies had no role in study design or conduct, or in the writing of this report. Drs. Aggarwal, Thompson, Shanholtz, and Checkley received support for article research from the National Institutes of Health (NIH). Dr. Aggarwal was supported by a Fellow-to-Faculty Award (11FTF7280014) from the American Heart Association. Dr. Brower received funding from Applied Clinical Intelligence and Global Blood Therapeutics. Dr. Thompson received funding from consultancy for Alexion, Asahi Kasei, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Vertex, and Regeneron unrelated to the current work. Dr. Shanholtz's institution received funding from the NIH National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Dr. Checkley was supported by a Pathway to Independence Award (R00HL096955) from the National Heart, Lung and Blood Institute, NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest. For information regarding this article, E-mail: wcheckl1@jhmi.edu Copyright © by 2017 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.

http://ift.tt/2BwO3NS